Paradigm Capital Management Inc. NY Has $23.40 Million Stock Position in Enovis Co. (NYSE:ENOV)

Paradigm Capital Management Inc. NY raised its holdings in Enovis Co. (NYSE:ENOV) by 2,566.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 533,200 shares of the company’s stock after acquiring an additional 513,200 shares during the quarter. Enovis accounts for 1.1% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 27th biggest holding. Paradigm Capital Management Inc. NY’s holdings in Enovis were worth $23,397,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Enovis in the 4th quarter valued at $29,000. Quadrant Capital Group LLC increased its stake in Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after purchasing an additional 239 shares in the last quarter. UMB Bank n.a. increased its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares in the last quarter. Quarry LP raised its holdings in shares of Enovis by 506.1% during the fourth quarter. Quarry LP now owns 897 shares of the company’s stock valued at $39,000 after purchasing an additional 749 shares during the period. Finally, Sterling Capital Management LLC boosted its position in shares of Enovis by 56.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,259 shares of the company’s stock worth $143,000 after purchasing an additional 1,173 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Trading Down 1.7%

ENOV opened at $35.45 on Tuesday. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $52.76. The firm has a market capitalization of $2.03 billion, a PE ratio of -16.19 and a beta of 1.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The company’s 50-day moving average is $35.13 and its 200 day moving average is $41.37.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. During the same period in the prior year, the business posted $0.50 earnings per share. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. As a group, research analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Needham & Company LLC decreased their target price on Enovis from $64.00 to $57.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Enovis from $75.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Finally, JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.